ASPIK French is another phase 3 clinical trial whose goal is to determine local or distant recurrence or second CRC or death from any cause, whichever occurs first, in patients with surgically resected PI3K-mutated colon cancer taking 100 mg of daily aspirin as compared to placebo (ClinicalTrials.gov; NCT02945033). This evidence concerns the gene PIK3CA and colonic neoplasm.